title: A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis.
abstract: The nicotinic acetylcholine receptor alpha1 (nAChRalpha1) was investigated as a potential fibrogenic molecule in the kidney, given reports that it may be an alternative urokinase (urokinase plasminogen activator; uPA) receptor in addition to the classical receptor uPAR. In a mouse obstructive uropathy model of chronic kidney disease, interstitial fibroblasts were identified as the primary cell type that bears nAChRalpha1 during fibrogenesis. Silencing of the nAChRalpha1 gene led to significantly fewer interstitial alphaSMA(+) myofibroblasts (2.8 times decreased), reduced interstitial cell proliferation (2.6 times decreased), better tubular cell preservation (E-cadherin 14 times increased), and reduced fibrosis severity (24% decrease in total collagen). The myofibroblast-inhibiting effect of nAChRalpha1 silencing in uPA-sufficient mice disappeared in uPA-null mice, suggesting that a uPA-dependent fibroblastic nAChRalpha1 pathway promotes renal fibrosis. To further establish this possible ligand-receptor relationship and to identify downstream signaling pathways, in vitro studies were performed using primary cultures of renal fibroblasts. (35)S-Labeled uPA bound to nAChRalpha1 with a K(d) of 1.6 x 10(-8) m, which was displaced by the specific nAChRalpha1 inhibitor d-tubocurarine in a dose-dependent manner. Pre-exposure of uPA to the fibroblasts inhibited [(3)H]nicotine binding. The uPA binding induced a cellular calcium influx and an inward membrane current that was entirely prevented by d-tubocurarine preincubation or nAChRalpha1 silencing. By mass spectrometry phosphoproteome analyses, uPA stimulation phosphorylated nAChRalpha1 and a complex of signaling proteins, including calcium-binding proteins, cytoskeletal proteins, and a nucleoprotein. This signaling pathway appears to regulate the expression of a group of genes that transform renal fibroblasts into more active myofibroblasts characterized by enhanced proliferation and contractility. This new fibrosis-promoting pathway may also be relevant to disorders that extend beyond chronic kidney disease.
authors.affiliation: Division of Nephrology, Immunology, Seattle Children's Hospital Research Institute, Seattle, Washington 98101, USA. guoqiang.zhang@seattlechildrens.org
authors.forename: Guoqiang
authors.initials: G
authors.lastname: Zhang
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Kernan
authors.forename: Alison
authors.initials: A
authors.lastname: Thomas
authors.forename: Sarah
authors.initials: S
authors.lastname: Collins
authors.forename: Yumei
authors.initials: Y
authors.lastname: Song
authors.forename: Ling
authors.initials: L
authors.lastname: Li
authors.forename: Weizhong
authors.initials: W
authors.lastname: Zhu
authors.forename: Renee C
authors.initials: RC
authors.lastname: Leboeuf
authors.forename: Allison A
authors.initials: AA
authors.lastname: Eddy
mesh_terms: D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts / Q000378:metabolism*; D005355:Fibrosis / Q000473:pathology*; D007668:Kidney / Q000473:pathology*; D007674:Kidney Diseases / Q000378:metabolism; D013058:Mass Spectrometry / Q000379:methods; D051379:Mice; D008810:Mice, Inbred C57BL; D018733:Nicotinic Antagonists / Q000494:pharmacology; D011485:Protein Binding; D011978:Receptors, Nicotinic / Q000378:metabolism*; D015398:Signal Transduction; D014403:Tubocurarine / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
chemical_list: D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; D014568:Urokinase-Type Plasminogen Activator; D014403:Tubocurarine
references.citation: Anal Biochem. 1967 May;19(2):249-55
references.pmid: 6048697
references.citation: Nat Cell Biol. 2006 May;8(5):485-91
references.pmid: 16622418
references.citation: J Neurosci. 1994 May;14(5 Pt 2):3271-9
references.pmid: 8182471
references.citation: Front Biosci. 2008 May 01;13:5462-78
references.pmid: 18508599
references.citation: Thromb Res. 2007;120(6):871-6
references.pmid: 17331567
references.citation: Respir Res. 2004 Dec 10;5:27
references.pmid: 15588326
references.citation: FEBS J. 2007 Aug;274(15):3799-845
references.pmid: 17651090
references.citation: J Vasc Res. 2006;43(5):437-46
references.pmid: 16899994
references.citation: Biol Chem. 2003 Feb;384(2):229-36
references.pmid: 12675515
references.citation: J Biol Chem. 2000 Jun 2;275(22):16450-8
references.pmid: 10749881
references.citation: Proc Natl Acad Sci U S A. 1988 Jul;85(13):4894-7
references.pmid: 3164478
references.citation: Kidney Int. 2008 Jul;74(1):62-9
references.pmid: 18401335
references.citation: Am J Physiol Renal Physiol. 2007 Jul;293(1):F12-9
references.pmid: 17356128
references.citation: J Cell Sci. 2006 Aug 15;119(Pt 16):3424-34
references.pmid: 16882693
references.citation: J Biol Chem. 2006 Jun 2;281(22):15345-51
references.pmid: 16554301
references.citation: Nucleic Acids Res. 2001 Apr 1;29(7):1433-42
references.pmid: 11266543
references.citation: J Recept Signal Transduct Res. 1999 Nov;19(6):939-51
references.pmid: 10533982
references.citation: Kidney Int. 2000 Apr;57(4):1521-38
references.pmid: 10760088
references.citation: Scand J Clin Lab Invest. 1955;7(3):239-45
references.pmid: 13298600
references.citation: Drug News Perspect. 2008 Mar;21(2):107-16
references.pmid: 18389102
references.citation: Mol Biol Cell. 2006 Jan;17(1):367-78
references.pmid: 16267271
references.citation: FEBS Lett. 1994 Aug 1;349(2):163-8
references.pmid: 8050560
references.citation: Nature. 1994 Mar 31;368(6470):419-24
references.pmid: 8133887
references.citation: Hum Gene Ther. 1999 Jul 1;10(10):1735-7
references.pmid: 10428218
references.citation: J Submicrosc Cytol Pathol. 2005 Aug;37(2):109-204
references.pmid: 16335592
references.citation: J Physiol. 2003 Aug 15;551(Pt 1):155-68
references.pmid: 12824448
references.citation: J Infect Dis. 2005 Aug 1;192(3):429-37
references.pmid: 15995956
references.citation: Adv Chronic Kidney Dis. 2005 Oct;12(4):353-65
references.pmid: 16198274
references.citation: Exp Eye Res. 2009 Aug;89(2):133-9
references.pmid: 19285070
references.citation: Med Hypotheses. 1997 Jul;49(1):57-9
references.pmid: 9247909
references.citation: FEBS Lett. 2003 Jul 31;548(1-3):113-8
references.pmid: 12885417
references.citation: Hypertension. 1997 Apr;29(4):1007-13
references.pmid: 9095091
references.citation: J Cell Biol. 1989 Feb;108(2):637-45
references.pmid: 2465296
references.citation: J Biol Chem. 2008 Mar 7;283(10):6312-20
references.pmid: 18174170
references.citation: J Am Soc Nephrol. 2003 May;14(5):1254-71
references.pmid: 12707394
references.citation: J Biol Chem. 1998 Dec 11;273(50):33267-72
references.pmid: 9837898
references.citation: Blood Coagul Fibrinolysis. 2004 Jul;15(5):383-91
references.pmid: 15205586
references.citation: Trends Immunol. 2004 Aug;25(8):450-5
references.pmid: 15275645
references.citation: Proc Natl Acad Sci U S A. 1986 Jan;83(2):498-502
references.pmid: 3455784
references.citation: Thromb Haemost. 1994 Jan;71(1):19-25
references.pmid: 8165642
references.citation: Adv Clin Chem. 2008;45:31-45
references.pmid: 18429492
references.citation: J Cell Biol. 1985 Jan;100(1):86-92
references.pmid: 3880760
references.citation: J Am Soc Nephrol. 2003 May;14(5):1234-53
references.pmid: 12707393
references.citation: J Am Soc Nephrol. 2004 Aug;15(8):2090-102
references.pmid: 15284295
references.citation: J Am Soc Nephrol. 2007 Mar;18(3):846-59
references.pmid: 17267741
references.citation: J Am Soc Nephrol. 2002 Feb;13(2):411-422
references.pmid: 11805170
references.citation: EMBO J. 1990 Mar;9(3):783-90
references.pmid: 2311580
references.citation: Invest Ophthalmol Vis Sci. 1993 Apr;34(5):1876-9
references.pmid: 8473125
references.citation: Kidney Int. 2005 Jun;67(6):2221-38
references.pmid: 15882265
references.citation: Biochem Pharmacol. 2001 Mar 15;61(6):733-40
references.pmid: 11266659